一般演題1-7A 悪性リンパ腫：臨床試験

[OS1-7A-1] AUGMENT: phase III randomized study of lenalidomide+rituximab (R²) vs rituximab in R/R iNHL patients

John P. Leonard¹, Marek Trneny², Nathan H. Fowler³, Xiaonan Hong⁴, Jun Zhu⁵, Huilai Zhang⁶, Fritz Offner⁷, Adriana Scheliga⁸, Grzegorz Nowakowski⁹, Antonio Pinto¹⁰, Francesca Re¹¹, Laura Maria Fogliatto¹², Phillip Scheinberg¹³, Ian Flinn¹⁴, Claudia Moreira¹⁵, Myron Czuczman¹⁶, Stacey Kalambakas¹⁶, Pierre Fustier¹⁷, Chengqing Wu¹⁶, John Gribben¹⁸, Koji Izutsu¹⁹ (1.Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY, United States of America, 2.Charles University Hospital, Prague, Czech Republic, 3.The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America, 4.Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China, 5.Beijing Cancer Hospital, Beijing, People's Republic of China, 6.Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China, 7.UZ Gent, Gent, Kingdom of Belgium, 8.INCA Instituto Nacional de Cancer, Rio de Janeiro, Federative Republic of Brazil, 9.Mayo Clinic, Rochester, MN, United States of America, 10.Istituto Nazionale Per Lo Studio E La Cura dei Tumori Fondazione Giovanni Pascale, Napoli, Italian Republic, 11.Azienda Ospedaliero-Universitaria di Parma, Parma, Italian Republic, 12.Hospital de Clinicas de Porto Alegre, Porto Alegre, Federative Republic of Brazil, 13.Division of Hematology, Hospital A Beneficencia Portuguesa, Sao Paulo, Federative Republic of Brazil, 14.SCRI Tennessee Oncology Nashville, Nashville, TN, United States of America, 15.Instituto Portugues de Oncologia do Porto Francisco Gentil Epe, Porto, Portuguese Republic, 16.Celgene Corporation, Summit, NJ, United States of America, 17.Celgene Corporation, Boudry, Swiss Confederation, 18.Centre for Haemato-Oncology, Barts Cancer Institute, London, United Kingdom of Great Britain and Northern Ireland, 19.National Cancer Center Hospital, Tokyo, Japan)